Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Skybiotech HealthcareBOM:512036 -0.30%23 Gross Margin % is 26.76% as of Mar. 2026, which is 43% below its 10-year median of 46.80. GuruFocus rates BOM:512036 with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 506 Conglomerates companies, Skybiotech Healthcare ranks better than 81.62% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Skybiotech Healthcare had a gross margin of 26.76% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Skybiotech Healthcare Gross Margin % Related Terms
Skybiotech Healthcare Gross Margin % Historical Data
* Premium members only.
The historical data trend for Skybiotech Healthcare's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Conglomerates subindustry, Skybiotech Healthcare's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Skybiotech Healthcare Gross Margin % vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, Skybiotech Healthcare's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Skybiotech Healthcare's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Skybiotech Healthcare (BOM:512036) has a Gross Margin % of 26.76% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Skybiotech Healthcare and its competitors. This is 43% below median its historical median of 46.80. Over the past decade, Skybiotech Healthcare's Gross Margin % has ranged from 6.91 to 71.01. According to the industry distribution chart, Skybiotech Healthcare ranks #93 out of 506 companies in the Conglomerates industry, placing it in the top 18.4%.
Is Skybiotech Healthcare's Gross Margin % too high?
Skybiotech Healthcare's current Gross Margin % of 26.76% is 43% below median its 10-year median of 46.80. Over the past 10 years, this metric has ranged from a low of 6.91 to a high of 71.01. The Conglomerates industry median Gross Margin % is 26.05. Skybiotech Healthcare's value of 26.76% is 2.7% above this industry median. Based on the distribution chart, Skybiotech Healthcare ranks #93 out of 506 companies in the Conglomerates industry, which is in the top quartile — a strong position relative to peers. Overall, Skybiotech Healthcare has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Skybiotech Healthcare's Gross Margin % compare to MMM and HON?
According to the Conglomerates industry distribution chart, Skybiotech Healthcare ranks #93 out of 506 companies for Gross Margin %. This places Skybiotech Healthcare in the top 18% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 26.05. Skybiotech Healthcare's value of 26.76% is 2.7% above this benchmark. Historically, Skybiotech Healthcare's own Gross Margin % has ranged from 6.91 to 71.01 over the past decade. While the company's 10-year median is 46.80 vs. the industry median of 26.05, Skybiotech Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Conglomerates company?
The median Gross Margin % among Conglomerates companies is 26.05, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Skybiotech Healthcare's current Gross Margin % of 26.76% is 2.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Skybiotech Healthcare and its competitors. For the Conglomerates industry, the median Gross Margin % is 26.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Skybiotech Healthcare's current Gross Margin % is 26.76%, which is 43% below median its own 10-year median of 46.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skybiotech Healthcare stock overvalued right now?
Skybiotech Healthcare (BOM:512036) has a current Gross Margin % of 26.76%. The current Gross Margin % is 26.76%, which is 43% below median its 10-year median of 46.80 and 2.7% above the Conglomerates industry median of 26.05. Skybiotech Healthcare's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Skybiotech Healthcare (BOM:512036), the current Gross Margin % is 26.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Skybiotech Healthcare Ltd, formerly Kapil Cotex Ltd is engaged in textiles and allied products, including dyeing, printing, spinning, weaving, and manufacturing fabrics from raw cotton. During the year under review, the company has not generated any revenue from its core business activities. Instead, it earned income from consultancy services for foreign clients and from investments in shares, generating capital gains and dividends. The company's current revenue mainly comes from these non-core activities rather than textile manufacturing.
23GF Score
Get the complete analysis for BOM:512036
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:512036 has been successfully added to your 
